Company Overview of Xenova Group PLC
Xenova Group PLC develops drugs for the treatment of cancer and addiction, with a secondary focus on immunology. The company develops three cancer programs that include TransMIDTM, which is in Phase III trials for the treatment of high-grade glioma; and DNA targeting agents and XR303 that are in Phase I for cancer indications. The company also develops therapeutic vaccines for cocaine and nicotine addiction, which are in Phase II and Phase I trials respectively. The company was founded in 1987 and is based in Slough, United Kingdom. Xenova Group PLC operates as a subsidiary of Celtic Pharma Development UK Plc. As of April 15, 2014, Xenova Group PLC is in liquidation.
957 Buckingham Avenue
Slough, SL1 4NL
Founded in 1987
44 17 5370 6600
44 17 5370 6607
Key Executives for Xenova Group PLC
Similar Private Companies By Industry
|Pfizer Group Ltd.||Europe|
|Miro Omega-3 Limited||Europe|
|ProStrakan Group PLC||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact Xenova Group PLC, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.